MedPath

Henan Cancer Hospital

Henan Cancer Hospital logo
🇨🇳China
Ownership
Private
Established
1977-01-01
Employees
-
Market Cap
-
Website
http://www.anti-cancer.com.cn

Clinical Trials

204

Active:7
Completed:13

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:27
Phase 2:100
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (173 trials with phase data)• Click on a phase to view related trials

Phase 2
100 (57.8%)
Not Applicable
32 (18.5%)
Phase 1
27 (15.6%)
Phase 3
8 (4.6%)
Phase 4
4 (2.3%)
Early Phase 1
2 (1.2%)

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

Not Applicable
Not yet recruiting
Conditions
Advanced Breast Cancer
Interventions
First Posted Date
2025-08-15
Last Posted Date
2025-08-15
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
60
Registration Number
NCT07125950
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

Not Applicable
Not yet recruiting
Conditions
Resectable Stage II-IIIB NSCLC
Interventions
Drug: Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab
First Posted Date
2025-08-07
Last Posted Date
2025-08-07
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
52
Registration Number
NCT07108816

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases

Not Applicable
Recruiting
Conditions
HER2-positive Advanced Breast Cancer
Brain Metastases
Radiotherapy
Interventions
Radiation: FSRT or WBRT
First Posted Date
2025-08-03
Last Posted Date
2025-08-11
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
224
Registration Number
NCT07100600
Locations
🇨🇳

Professor, Zhengzhou, Henan, China

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Not Applicable
Recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
812
Registration Number
NCT07057427
Locations
🇨🇳

Henan cancer hospital, Zhengzhou, Henan, China

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Not Applicable
Not yet recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2025-07-02
Last Posted Date
2025-07-02
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
48
Registration Number
NCT07047755
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 41
  • Next

News

Immunotherapy-Enhanced Total Neoadjuvant Therapy Shows Promise for Locally Advanced Rectal Cancer

Two multi-institutional studies demonstrate that combining immune checkpoint inhibitors with total neoadjuvant therapy (TNT) achieves superior pathological complete response rates compared to standard chemoradiotherapy in microsatellite stable locally advanced rectal cancer patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.